Theodora Calogeropoulou - Medicinal Chemistry

Theodora Calogeropoulou  Hosting Lab description 

Dr Theodora Calogeropoulou NHRF laboratory of chemical biology is organized for the design and synthesis of biologically active molecules. In particular:
a) Design and synthesis of antiprotozoal ether phospholipids and bioisosteres
b) Design and synthesis of novel neuroprotective and neuroregenerative small molecule neurotrophin mimetics 

c)Design and synthesis of heterocyclic compounds with multifunctional pharmacological profile: 

·       Possessing neuroprotective activity 

·       Tyrosinase modulators 

d) Design and synthesis of BRAFV600E inhibitors for the development of agents against colorectal cancer.
e) Design and synthesis of proteasome activators against aging.
f) Design and synthesis of fluorescent bioactive compounds and smart probes for target engagement studies and imaging. 

A parallel research activity involves the development of synthetic methodology using conventional techniques and microwave or ultrasound irradiation. 

The lab is fully equipped for the development of synthetic approaches. Dr. Calogeropoulou has a strong motivation to synthesize a number of compounds the published in high impact journals. The number of compounds is very high and she has experience in the field. Her team will also be available for discussion and final outcome.

Website : http://www.eie.gr/nhrf/institutes/icb/research_groups/CalogeropoulouTheodora_group_en.html

Hosting Lab selection motivation for the COST Action

Theodora Calogeropoulou’s lab has a long-standing expertise and positioning within the medicinal chemistry laboratory in Europe. She is the WG2 leader and responsible of the progression of the WG1 activity within OneHealthdrugs.